Pensionfund Sabic Sells 1,000 Shares of Humana Inc. (NYSE:HUM)

Pensionfund Sabic lessened its holdings in Humana Inc. (NYSE:HUM) by 33.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,000 shares of the insurance provider’s stock after selling 1,000 shares during the quarter. Pensionfund Sabic’s holdings in Humana were worth $633,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. raised its holdings in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. Atwood & Palmer Inc. bought a new stake in Humana during the third quarter worth $29,000. Hantz Financial Services Inc. acquired a new position in Humana during the 2nd quarter worth approximately $35,000. Family Firm Inc. bought a new position in Humana in the second quarter valued at about $37,000. Finally, Hollencrest Capital Management acquired a new position in shares of Humana during the second quarter worth $40,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 2.4 %

HUM opened at $251.36 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The stock’s 50 day moving average price is $329.03 and its 200-day moving average price is $341.40. Humana Inc. has a one year low of $213.31 and a one year high of $530.54. The stock has a market cap of $30.26 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted $8.94 earnings per share. On average, equities analysts forecast that Humana Inc. will post 16.06 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 25.25%.

Wall Street Analyst Weigh In

Several research firms recently commented on HUM. Royal Bank of Canada decreased their target price on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday. UBS Group dropped their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Stephens reiterated an “equal weight” rating and set a $250.00 price objective on shares of Humana in a research note on Wednesday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Finally, Bank of America cut shares of Humana from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $376.00 to $247.00 in a research report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and six have given a buy rating to the company. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $322.00.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.